SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 28th, 2019 • Therapix Biosciences Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 28, 2019, between Therapix Biosciences Ltd., an Israeli corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES THERAPIX BIOSCIENCES LTD.Warrant Agreement • March 28th, 2019 • Therapix Biosciences Ltd. • Pharmaceutical preparations
THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [_______, March [__], 2019 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on March [__], 2022 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Therapix Biosciences Ltd., a company organized under the laws of the State of Israel (the “Company”), up to ______ Ordinary Shares (the “Warrant Shares”) represented by American Depositary Shares (“ADSs”), as subject to adjustment hereunder, and the ADSs issuable upon exercise of this Warrant the “Warrant ADSs”). The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b).
